DUBLIN, May 27, 2015 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/pjjddf/us_cancer_vaccine) has announced the addition of the "US Cancer Vaccine Market Outlook 2020" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
Cancer vaccines could be divided into to two broad categories of prophylactic (preventive) and therapeutic (treatment) segments. In US, cancer vaccines belong to both of these groups have been marketed in past few decades. Food and Drug Administration (FDA) is taking effective measures to offer better medical care to cancer patients. They are willing to try newer modalities due to which pharmaceutical companies are actively engaged for developing them for different malignancies.
Due to this reason cancer vaccines got marketing approval in US and in clinical trials they have generated significant data. Increasing demand and higher acceptance rates among patients are expected to increase their sales due to which pharmaceutical companies are actively competing to generate more revenues from this segment. In future, number of clinical trials is expected to increase to develop cancer vaccines for different malignancies. Some of the products are different stages of clinical trials which are expected to be commercialized in US in coming years.
Cancer vaccines for malignancies developed as a result of infectious agents has gained acceptance in past few years and success of HPV vaccines in encourages pharmaceutical companies to invest significantly in this segment. Moreover, FDA has already approved hepatitis B vaccine for hepatic carcinoma but cure for hepatitis C remains elusive. This segment may develop a whole new segment of cancer vaccines and time will tell about success of these measures. In future, it may happen that cancer vaccines for various malignancies caused by infectious agents will become easily available in US. Main emphasis is being given on Kaposi's sarcoma which is Human Immunodeficiency Virus (HIV) associated malignancy.
Till date no effective treatment for Kaposi's sarcoma is available but by activating patients' immune system with the help of cancer vaccines it could be treated. In recent years, investigators have been able to find putative link between H. pyroli and gastric cancer. These indices have less frequency but these cases are increasing and there are no competitive products in US market as a result of which significant opportunity to churn significant revenues exists for pharmaceutical companies.
US is expected to become one of the largest market for cancer vaccines due to amenable regulatory rules for newly developed medicinal products. FDA is known to provide early marketing approval to products if breakthrough is produced at early stages of clinical trials. This will allow the cancer patients use cancer vaccine for their treatment without waiting for long time. Recently, US has agreed to introduce lung cancer vaccine developed in Cuba to be used in clinical trials for checking its safety and efficacy. If this lung cancer vaccine proves its worth in clinical trials performed in US, then it will get marketing approval. Due to increasing cancer incidences, it has become necessary to take such steps which will help the large population base suffering from different malignancies. Hopefully, pharmaceutical companies will try to take introduce their cancer vaccines as soon as possible in US to occupy major market shares due to which more cancer patients will get highly effective cancer vaccines.
"US Cancer Vaccine Market Outlook 2020" Report Highlight:
- US Cancer Vaccine Market Analysis
- Cancer Vaccine with Orphan Status
- US Cancer Vaccine Clinical Pipeline by Company, Indication & Phase
- US Cancer Vaccine Clinical Pipeline: 187 Vaccines
- Clinical Insight of Marketed Cancer Vaccines in US
- Marketed Cancer Vaccine in US: 5 Vaccines
- FDA Regulations for Clinical Trials of Cancer Vaccines
Clinical Insight of Marketed Cancer Vaccines in US
- Bladder Cancer Vaccine - ID Biomedical (PACIS®)
- Bladder Cancer Vaccine - Organon Teknika (OncoTICE)
- Human Papillomavirus Vaccine Quadrivalent - Merck (Gardasil®)
- Human Papillomavirus Vaccine Recombinant Bivalent - GlaxoSmithKline/MedImmune (Cervarix®)
- Prostate Cancer - Dendreon Corporation (Provenge®)
- Aduro BioTech
- Antigen Express
- Argos Therapeutics
- Bavarian Nordic
- Celldex Therapeutics
- Cosmo Pharmaceuticals
- Dendreon Corporation
- Galena Biopharma
- Generex Biotechnology
- NewLink Genetics
- Oxford BioMedica
For more information visit http://www.researchandmarkets.com/research/pjjddf/us_cancer_vaccine
Media Contact: Laura Wood , +353-1-481-1716, email@example.com